HEMOBIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers

Show all filings for HEMOBIOTECH, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for HEMOBIOTECH, INC. 29-Oct-2009Change in Directors or Principal Officers Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only,...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Financials

PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue -   -   -   -  Cost of Revenue -   -   -   -  Gross Profit -   -   -   -  Operating ExpensesResearch Development108  77  (66)276  Selling General and Administrative394  388  485  365  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(502)(465)(419)(641)Income from Continuing OperationsTotal Other Income/Expenses Net -  3  4  5  Earnings Before Interest And Taxes(502)(462)(415)(636)Interest Expense -   -   -   -  Income Before Tax(502)(462)(415)(636)Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(502)(462)(415)(636)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   ...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS PLAN OF OPERATIONS We are primarily engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center ("TTUHSC"). Since October 27, 2004 most of our working capital was used to pay for general and administrative costs, salaries, legal and accounting fees and the cost of raising money. After reviewing the blood substitute technology developed by researchers at Texas Tech, in January 2002 we licensed from Texas Tech the exclusive rights to various alternative compositions of HemoTech, a novel blood substitute that is based on hemoglobin (which is the key protein in red blood cells that carries oxygen) of both bovine (cow) and human origin, as well as methods for its production and use. What makes HemoTech a novel potential blood substitute product is the fact that it is comprised of hemoglobin that has been isolated from bovine blood and then chemically modified to make the product non-toxic. We also have an agreement with Texas Tech that any patent issued from its patent application relating to the induction of erythropoiesis (which is the production of red blood cells by the body) will be included under our exclusive license with Texas Tech. In addition to our license and patent agreement with Texas Tech, beginning in July 2002, we have entered into a series of Sponsored Research Agreements ("SRA") with TTUHSC under which we are entitled to use certain of Texas Tech's production and research and development facilities in Lubbock, Texas. In January 2007, the Company entered into a Stage IV SRA with TTUHSC for the period beginning January 1, 2007. In connection therewith, the Company made an initial payment of approximately $780,000. This amount will be charged to operations over the period of the research (see Note D to the Condensed Financial Statements). Additional pa...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report

Expired Yahoo - Document Has Expired/e/090818/hmbte.ob10-q.html Options that might be of interest: Go to the Yahoo! home page. Go to the Yahoo! Finance home page. Go to the Yahoo! Loan Center. Go to the Yahoo! Insurance Center. Other resources: Message Boards - Stock Chat - Finance Clubs ...
Click here to read the whole Article (external link)

HemoBioTech Gains Congressional Recognition of Its Blood Substitute Technology

DALLAS, TX--(Marketwire - 08/17/09) - HemoBioTech, Inc. (OTC.BB:HMBT - News) has been working with a coalition of small biotechnology firms to implement legislation that will strengthen the Federal government's stewardship role in the protection and preservation of pre-revenue biotechnology companies. In addition, the HemoBioTech's blood substitute technology recently gained support from the office of Rep. Edolphus Towns of New York, whose office circulated a letter to House Members addressing the urgent need for a blood substitute to prevent HIV AIDS from HIV contaminated blood, especially in the world's poorest nations. Cited in the letter is the use of hemoglobin modified with adenosine as a viable blood substitute. Adenosine modified hemoglobin is a fundamental feature of HemoTech which is being developed by HemoBioTech as the first viable blood substitute and is patented in 21 countries. Congressman Towns also supports an investment of $35 million and a proposal to work with the FDA to fast tract the development of the technology. The full letter follows this release."Congressional recognition is critical as HemoBioTech advances through the development of HemoTech, its adenosine modified hemoglobin blood substitute," said HemoBioTech's Chairman and CEO, Arthur P. Bollon, Ph.D. "We look forward to working with Congressman Towns and other members of Congress in implementing these proposals."About HemoBioTech, Inc.HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substi...
Click here to read the whole Article (external link)

HemoBioTech to Present "Need for Blood Substitute to Prevent HIV Transmission" at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention

Expired Yahoo - Document Has Expired/iw/090602/0506711.html Options that might be of interest: Go to the Yahoo! home page. Go to the Yahoo! Finance home page. Go to the Yahoo! Loan Center. Go to the Yahoo! Insurance Center. Other resources: Message Boards - Stock Chat - Finance Clubs ...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS PLAN OF OPERATIONS We are primarily engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center ("TTUHSC"). Since October 27, 2004 most of our working capital was used to pay for general and administrative costs, salaries, legal and accounting fees and the cost of raising money. After reviewing the blood substitute technology developed by researchers at Texas Tech, in January 2002 we licensed from Texas Tech the exclusive rights to various alternative compositions of HemoTech, a novel blood substitute that is based on hemoglobin (which is the key protein in red blood cells that carries oxygen) of both bovine (cow) and human origin, as well as methods for its production and use. What makes HemoTech a novel potential blood substitute product is the fact that it is comprised of hemoglobin that has been isolated from bovine blood and then chemically modified to make the product non-toxic. We also have an agreement with Texas Tech that any patent issued from its patent application relating to the induction of erythropoiesis (which is the production of red blood cells by the body) will be included under our exclusive license with Texas Tech. In addition to our license and patent agreement with Texas Tech, beginning in July 2002, we have entered into a series of Sponsored Research Agreements ("SRA") with TTUHSC under which we are entitled to use certain of Texas Tech's production and research and development facilities in Lubbock, Texas. In January 2007, the Company entered into a Stage IV SRA with TTUHSC for the period beginning January 1, 2007. In connection therewith, the Company made an initial payment of approximately $780,000. This amount will be charged to operations over the period of the research (see Note D to the Condensed Financial Statements). Additional pa...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Files SEC form 10-K, Annual Report

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS PLAN OF OPERATIONS We are primarily engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center ("TTUHSC"). Since October 27, 2004 most of our working capital was used to pay for general and administrative costs, salaries, legal and accounting fees and the cost of raising money. After reviewing the blood substitute technology developed by researchers at Texas Tech, in January 2002 we licensed from Texas Tech the exclusive rights to various alternative compositions of HemoTech, a novel blood substitute that is based on hemoglobin (which is the key protein in red blood cells that carries oxygen) of both bovine (cow) and human origin, as well as methods for its production and use. What makes HemoTech a novel potential blood substitute product is the fact that it is comprised of hemoglobin that has been isolated from bovine blood and then chemically modified to make the product non-toxic. We also have an agreement with Texas Tech that any patent issued from its patent application relating to the induction of erythropoiesis (which is the production of red blood cells by the body) will be included under our exclusive license with Texas Tech. In addition to our license and patent agreement with Texas Tech, beginning in July 2002, we have entered into a series of Sponsored Research Agreements ("SRA") with TTUHSC under which we are entitled to use certain of Texas Tech's production and research and development facilities in Lubbock, Texas. In January 2007, the Company entered into a Stage IV SRA with TTUHSC for the period beginning January 1, 2007. In connection therewith, the Company made an initial payment of approximately $780,000. This amount will be charged to operations over the period of the research (see Note D to the Financial Statements). Additional payments may...
Click here to read the whole Article (external link)

HEMOBIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

Show all filings for HEMOBIOTECH, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for HEMOBIOTECH, INC. 9-Mar-2009Change in Directors or Principal Officers, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "a...
Click here to read the whole Article (external link)